Document is current
Any future updates will be listed below
-
Authors
Acar, Ahmet
Nichol, Daniel http://orcid.org/0000-0003-2662-1836
Fernandez-Mateos, Javier
Cresswell, George D. http://orcid.org/0000-0003-3303-068X
Barozzi, Iros
Hong, Sung Pil
Trahearn, Nicholas
Spiteri, Inmaculada http://orcid.org/0000-0002-1097-8972
Stubbs, Mark
Burke, Rosemary
Stewart, Adam
Caravagna, Giulio
Werner, Benjamin http://orcid.org/0000-0002-6857-8699
Vlachogiannis, Georgios http://orcid.org/0000-0003-3114-8772
Maley, Carlo C. http://orcid.org/0000-0002-0745-7076
Magnani, Luca http://orcid.org/0000-0002-7534-0785
Valeri, Nicola
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Sottoriva, Andrea http://orcid.org/0000-0001-6709-9533
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (RP-2016-07-28)
Cancer Research UK (A25128, A22897, A22909)
Wellcome Trust (202778/B/16/Z, 105104/Z/14/Z)
- License Information
-
More Information
Article History
Received: 8 October 2019
Accepted: 18 March 2020
First Online: 21 April 2020
Competing interests
: U.B. has received funding for investigator-initiated clinical trials for a phase I study of vistusertib and paclitaxel from Astra Zeneca. U.B. has received funding for investigator initiated clinical trials for a phase I study of a dual MEK-RAF inhibitor RO5126766 from Chugai. NV received honoraria for lectures from Merck Serono, Pfizer, Bayer and Eli-Lilly. Neither company has funded or had input into research presented in this manuscript. All other authors declare no competing interests.
